The FDA is reviewing Roche's giredestrant for post-surgery and advanced breast cancer treatment. Trial gains, evidence gaps and affordability will shape its wider significance.Swiss pharma giant Roche has a daily breast cancer pill in front of the US Food and Drug Administration, and a verdict is close.
The drug, giredestrant, is still experimental, and no regulator has cleared it anywhere – what is known about it comes from clinical trials.This week, Roche told Bloomberg it sees sales of up to $15 billion once the pill hits the markets.Priority review is already been granted, and the FDA has until 30 November to rule on its use after surgery, while 18 December on a separate filing for advanced disease.The investigational drug has generated interest as breast cancer has become a major public health problem globally and has emerged as the most common cancer among women worldwide. As per the World Health Organisation – international Agency for Research in Cancer (WHO-IARC)’s GLOBOCAN 2024 statistics, there were 24.34 lakh new cancer cases detected that year worldwide, accounting for roughly 11.8% of all cancer diagnoses.India reported about 2.37 lakh new breast cancer cases in 2024, the highest among all malignancies, as per the same database.TRIAL DATA SO FAR Giredestrant targets tumours that are hormone receptor-positive and HER2-negative, meaning oestrogen helps drive their growth.
It belongs to a class called selective oestrogen receptor degraders, which block the receptor and break it down.Fulvestrant and elacestrant are older members of the class. Roche argues its pill is easier to tolerate than these.
The case for post-surgery use rests on lidERA, which enrolled about 4,100 people with stage I to III disease.Against standard hormone therapy, giredestrant lowered the risk of invasive recurrence or death by 30%. After three years, 92.4% of those on the new pill had no invasive disease, compared with 89.6% on the standard drug.Side effects led 5.3% to stop the pill, against 8.2% on standard therapy.The advanced-disease filing leans on evERA, the phase 3 global clinical trial evaluating treatments for advanced breast cancer.Patients whose cancer had progressed after earlier treatment received giredestrant alongside everolimus.
Their risk of progression or death fell 44% overall and 62% among those with an ESR1 mutation. The New England Journal of Medicine published the trial results early this month.GAPS IN EVIDENCENot every trial has delivered the desired results.
In persevERA, giredestrant was paired with palbociclib as the first treatment for metastatic disease. Patients lived longer without progression, but the gain did not clear the statistical bar the trial had set in advance.
An earlier report had said the study missed its primary endpoint.Design and duration also limit what lidERA, another study to assess the drug in post-surgery patients, can say. It was open-label, so patients and doctors knew who was taking what.
Three years of follow-up is short for a cancer that can return long after treatment, and the survival picture will take longer to settle.There is a commercial story too. Roche built its breast cancer franchise on Herceptin, launched more than 20 years ago, and has since lost ground to rivals, among them AstraZeneca with Enhertu.
A pill that works across early and advanced disease would give the company a fresh claim on that market.Approval in the US would be only the first step. Giredestrant would still need clearance from other regulators and a price that works outside rich countries, where a large share of breast cancer deaths occur, experts underline.- Ends